Guggenheim Maintains Buy on Insmed, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $52 to $54.
February 27, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Vamil Divan reaffirms a Buy rating on Insmed and increases the price target from $52 to $54.
The upgrade in price target by a reputable analyst like Vamil Divan from Guggenheim signals a positive outlook on Insmed's stock, likely leading to increased investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100